HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute myeloid leukemia after infliximab: a case report.

Abstract
Concern has arisen regarding a possible increase in the risk of malignant diseases such as lymphoproliferative disorders in a patient taking TNF-alpha antagonists for the treatment of chronic inflammatory diseases. The evidence of a causal link remains unclear. We report a case of 60-year-old male patient who developed acute myeloid leukemia during infliximab therapy for ankylo-sing spondylitis.
AuthorsF Kemta Lekpa, K Zahra, C Pautas, S Maury, X Chevalier, P Claudepierre
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2009 Nov-Dec Vol. 27 Issue 6 Pg. 999-1000 ISSN: 0392-856X [Print] Italy
PMID20149321 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Antibodies, Monoclonal (adverse effects)
  • Antirheumatic Agents (adverse effects)
  • Humans
  • Infliximab
  • Leukemia, Myeloid, Acute (chemically induced)
  • Male
  • Middle Aged
  • Spondylitis, Ankylosing (therapy)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: